13/01/2022 - Abivax SA: Abivax reçoit l'avis scientifique de l'EMA soutenant l'avancement du programme clinique de phase 3 d'ABX464 dans la rectocolite hémorragique

[X]
Abivax reçoit l'avis scientifique de l'ema soutenant l'avancement du programme clinique de phase 3 d'abx464 dans la rectocolite hémorragique

The text version of this document is not available. You can access the original document here.

Disclaimer

Abivax SA published this content on 13 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 January 2022 08:25:34 UTC.

MoneyController ti propone anche

Condividi